Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675659 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4511060 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4505249 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL2633192 | 0.87 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL6104864 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4508279 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL12288702 | 0.86 | CNR1 (0.84) | CNR1CNR2 | |
| Dimethylamine SCHEMBL1041936 | 0.85 | CNR1 (0.96) | CNR1CNR2 | |
| SCHEMBL10144577 | 0.85 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL674305 | 0.84 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | claimed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | claimed |
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.